Asset profile
Sintilimab
Monoclonal antibody
Partialdesign only
Evidence outlook · results not reported
ORIENT-3 (NCT03150875) · Non-small Cell Lung Cancer
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
ORIENT-3 (NCT03150875): The trial randomized 290 participants to sintilimab or active docetaxel control, with 145 versus 135 participants included in the reported overall-survival analysis, but treatment was open-label rather than blinded. Results were not posted at the time of grading; the key result shown was recorded subsequently from the registry record.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
83 competitors in this universe: 22 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 61 further along in development.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Sintilimab: this drug | Phase 3 | Monoclonal antibody | PD-1 | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Nivolumab | Approved | Monoclonal antibody | PD-1 | ||
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | ||
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | ||
| Pembrolizumab Berahyaluronidase Alfa | Approved | Monoclonal antibody | PD-1 | ||
| Retifanlimab | Approved | Monoclonal antibody | PD-1 | ||
| Toripalimab | Approved | Monoclonal antibody | PD-1 | ||
| Abp 234 | Phase 3 | Monoclonal antibody | PD-1 | ||
| Balstilimab | Phase 3 | Monoclonal antibody | PD-1 | ||
| Camrelizumab | Phase 3 | Monoclonal antibody | PD-1 | ||
| Cetrelimab | Phase 3 | Monoclonal antibody | PD-1 | ||
| CT-P51 | Phase 3 | Small molecule | PD-1 | ||
| Dostarlimab | Phase 3 | Monoclonal antibody | PD-1 | ||
| Enlonstobart | Phase 3 | Monoclonal antibody | PD-1 | ||
| MB12 | Phase 3 | Monoclonal antibody | PD-1 |
…and 68 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
vs Cemiplimab · Non-Small Cell Lung Cancervs Nivolumab · Non-Small Cell Lung Cancervs Pembrolizumab · Non-Small Cell Lung Cancervs Retifanlimab · Non-Small Cell Lung Cancervs Toripalimab · Non-Small Cell Lung Cancervs Camrelizumab · Non-Small Cell Lung Cancer
16 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(171 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (27)
October 2026 (3)
Phase 2Colorectal Cancer Stage II, Colorectal Cancer Stage IIIActive not recruiting
Est. primary completion 2026-10-18 · NCT04304209 · CT.gov ↗
What to watch
Phase 2Gastric AdenocarcinomaActive not recruiting
Est. primary completion 2026-10-31 · NCT06667050 · CT.gov ↗
What to watch
Phase 3Hepatocellular Carcinoma Non-resectableRecruiting
Est. primary completion 2026-10-31 · NCT05608200 · CT.gov ↗
What to watch
November 2026 (1)
Early phase / not applicableHepatocellular CarcinomaActive not recruiting
Est. primary completion 2026-11 · NCT05621499 · CT.gov ↗
What to watch
December 2026 (23)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12 · NCT06198907 · CT.gov ↗
What to watch
Phase 2Neuroendocrine Carcinomas (NEC)Not yet recruiting
Est. primary completion 2026-12 · NCT07156019 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal Carcinoma (NPC)Not yet recruiting
Est. primary completion 2026-12 · NCT06680115 · CT.gov ↗
What to watch
Phase 3Gastric CancerRecruiting
Est. primary completion 2026-12 · NCT05918094 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-01 · NCT06714708 · CT.gov ↗
What to watch
Phase 2Peripheral T-cell LymphomaRecruiting
Est. primary completion 2026-12-01 · NCT04512534 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2026-12-01 · NCT07268677 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-17 · NCT06747169 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Breast CancerNot yet recruiting
Est. primary completion 2026-12-30 · NCT07254858 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer MetastaticNot yet recruiting
Est. primary completion 2026-12-30 · NCT07007767 · CT.gov ↗
What to watch
Phase 2Natural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeRecruiting
Est. primary completion 2026-12-30 · NCT06314334 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-30 · NCT06031285 · CT.gov ↗
What to watch
Phase 3Colorectal Cancer Stage IVActive not recruiting
Est. primary completion 2026-12-30 · NCT05171660 · CT.gov ↗
What to watch
Phase 1/2Gastric (Stomach) CancerRecruiting
Est. primary completion 2026-12-31 · NCT06742411 · CT.gov ↗
What to watch
Phase 1/2Head and Neck Cancer, Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06494943 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, Anti-PD-1Not yet recruiting
Est. primary completion 2026-12-31 · NCT05998122 · CT.gov ↗
What to watch
Phase 2Colon AdenocarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT07468630 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2026-12-31 · NCT06555471 · CT.gov ↗
What to watch
Phase 2NeuroblastomaRecruiting
Est. primary completion 2026-12-31 · NCT06013618 · CT.gov ↗
What to watch
Phase 2Hepato Cellular Carcinoma (HCC)Recruiting
Est. primary completion 2026-12-31 · NCT06812039 · CT.gov ↗
What to watch
Phase 2HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06730373 · CT.gov ↗
What to watch
Phase 2Chronic Hepatitis BRecruiting
Est. primary completion 2026-12-31 · NCT07852091 · CT.gov ↗
What to watch
Early phase / not applicableEsophageal Squamous Cell Carcinoma (ESCC)Not yet recruiting
Est. primary completion 2026-12-31 · NCT07067450 · CT.gov ↗
What to watch
2027 (75)
January 2027 (1)
Phase 2Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)Recruiting
Est. primary completion 2027-01-15 · NCT07077512 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2Lung Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-02-28 · NCT06121505 · CT.gov ↗
What to watch
March 2027 (4)
Phase 1/2Locally Advanced Pancreatic Cancer, Metastatic Pancreatic CancerRecruiting
Est. primary completion 2027-03 · NCT06761027 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2027-03-10 · NCT06860490 · CT.gov ↗
What to watch
Phase 1Colorectal Cancer, AdultNot yet recruiting
Est. primary completion 2027-03-31 · NCT07411781 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-03-31 · NCT07492342 · CT.gov ↗
What to watch
April 2027 (7)
Phase 2HCC - Hepatocellular Carcinoma, Conversion TherapyRecruiting
Est. primary completion 2027-04 · NCT07560488 · CT.gov ↗
What to watch
Phase 1Head and Neck Squamous Cell Carcinoma HNSCCRecruiting
Est. primary completion 2027-04-01 · NCT07457281 · CT.gov ↗
What to watch
Phase 1/2Advanced Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2027-04-01 · NCT06995105 · CT.gov ↗
What to watch
Phase 1/2Pancreatic Cancer ResectableNot yet recruiting
Est. primary completion 2027-04-01 · NCT06888674 · CT.gov ↗
What to watch
Phase 1/2Advanced Intrahepatic CholangiocarcinomaRecruiting
Est. primary completion 2027-04-01 · NCT06956716 · CT.gov ↗
What to watch
Phase 1/2Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectableNot yet recruiting
Est. primary completion 2027-04-01 · NCT06888648 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma Non-resectableRecruiting
Est. primary completion 2027-04-30 · NCT06397222 · CT.gov ↗
What to watch
May 2027 (6)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-05 · NCT07014215 · CT.gov ↗
What to watch
Phase 2Small Cell Lung Cancer Extensive Stage, Resistance to ImmunotherapyNot yet recruiting
Est. primary completion 2027-05 · NCT07022301 · CT.gov ↗
What to watch
Phase 2AFP Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-05-01 · NCT06973330 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Esophagogastric Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-05-19 · NCT07658872 · CT.gov ↗
What to watch
Phase 2Lung CancerRecruiting
Est. primary completion 2027-05-30 · NCT06421298 · CT.gov ↗
What to watch
Phase 2Peritoneal Metastases, Gastric CancerNot yet recruiting
Est. primary completion 2027-05-30 · NCT06213519 · CT.gov ↗
What to watch
June 2027 (9)
Phase 2Gastric Cancer (Diagnosis)Not yet recruiting
Est. primary completion 2027-06-01 · NCT07669740 · CT.gov ↗
What to watch
Phase 2HCC - Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-06-01 · NCT07584018 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-06-01 · NCT06405113 · CT.gov ↗
What to watch
Phase 1/2Solid TumorNot yet recruiting
Est. primary completion 2027-06-30 · NCT07612137 · CT.gov ↗
What to watch
Phase 1/2Gastric CancerNot yet recruiting
Est. primary completion 2027-06-30 · NCT06426654 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal Cancer (LARC)Recruiting
Est. primary completion 2027-06-30 · NCT07040098 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerNot yet recruiting
Est. primary completion 2027-06-30 · NCT06502080 · CT.gov ↗
What to watch
Early phase / not applicableNon-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-06-30 · NCT06848426 · CT.gov ↗
What to watch
July 2027 (9)
Phase 1/2Gastric CancerRecruiting
Est. primary completion 2027-07 · NCT07025889 · CT.gov ↗
What to watch
Phase 2Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma, Resectable Oral and Oropharyngeal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-07 · NCT07079410 · CT.gov ↗
What to watch
Phase 2Cervical CarcinomaNot yet recruiting
Est. primary completion 2027-07 · NCT07088731 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer Liver MetastasisRecruiting
Est. primary completion 2027-07 · NCT06590259 · CT.gov ↗
What to watch
Phase 3Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant, Immune Checkpoint Inhibitor, TACE, Narrow MarginRecruiting
Est. primary completion 2027-07-09 · NCT07186621 · CT.gov ↗
What to watch
Phase 2Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-SCCHN)Not yet recruiting
Est. primary completion 2027-07-10 · NCT07310771 · CT.gov ↗
What to watch
Phase 2Gastric (Stomach) CancerNot yet recruiting
Est. primary completion 2027-07-25 · NCT06748508 · CT.gov ↗
What to watch
Phase 1/2Resectable Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-07-31 · NCT07714317 · CT.gov ↗
What to watch
Phase 3Hepatocellular Carcinoma Non-resectableRecruiting
Est. primary completion 2027-07-31 · NCT05985798 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer, Extensive-Stage Small-Cell Lung Cancer …Recruiting
Est. primary completion 2027-08-01 · NCT07061535 · CT.gov ↗
What to watch
Phase 2Resectable Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-08-25 · NCT07379424 · CT.gov ↗
What to watch
September 2027 (6)
Phase 2Locally Advanced Rectal CancerRecruiting
Est. primary completion 2027-09-01 · NCT06204094 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Esophagogastric Juction Cancer, Proficient Mismatch RepairNot yet recruiting
Est. primary completion 2027-09-01 · NCT07621562 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer Liver MetastasisRecruiting
Est. primary completion 2027-09-01 · NCT06788171 · CT.gov ↗
What to watch
Phase 3Esophageal Squamous Cell Carcinoma (ESCC)Enrolling by invitation
Est. primary completion 2027-09-01 · NCT07016737 · CT.gov ↗
What to watch
Phase 2Advanced Colorectal CancerNot yet recruiting
Est. primary completion 2027-09-15 · NCT07656766 · CT.gov ↗
What to watch
Phase 2Hepatoid Adenocarcinoma of StomachRecruiting
Est. primary completion 2027-09-20 · NCT07178340 · CT.gov ↗
What to watch
October 2027 (6)
Phase 4Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-10 · NCT06483009 · CT.gov ↗
What to watch
Phase 2Sebaceous Gland CarcinomaNot yet recruiting
Est. primary completion 2027-10-01 · NCT07740993 · CT.gov ↗
What to watch
Phase 2Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA, Pancreatic Cancer, Stage IIB, Pancreatic Cancer Stage IIINot yet recruiting
Est. primary completion 2027-10-01 · NCT05562297 · CT.gov ↗
What to watch
Phase 2Classical Hodgkin LymphomaRecruiting
Est. primary completion 2027-10-23 · NCT06848569 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-10-31 · NCT06604351 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-10-31 · NCT07309952 · CT.gov ↗
What to watch
November 2027 (2)
December 2027 (22)
Phase 1/2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-12 · NCT07522411 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07038460 · CT.gov ↗
What to watch
Phase 2BRAF V600E, Colorectal Cancer, Sintilimab, MSS (Microsatellite Stable), Cetuximab, Dabrafenib, Ipilimumab N01Recruiting
Est. primary completion 2027-12 · NCT07506109 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-12 · NCT07179900 · CT.gov ↗
What to watch
Phase 2GlioblastomaRecruiting
Est. primary completion 2027-12-01 · NCT07670026 · CT.gov ↗
What to watch
Phase 2Gastroesophageal Junction AdenocarcinomaActive not recruiting
Est. primary completion 2027-12-02 · NCT06739161 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-30 · NCT07748325 · CT.gov ↗
What to watch
Phase 2Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally AdvancedNot yet recruiting
Est. primary completion 2027-12-30 · NCT07018063 · CT.gov ↗
What to watch
Phase 2Adenocarcinoma of Small Intestine, Appendix Carcinoma, MetastaticRecruiting
Est. primary completion 2027-12-30 · NCT05472948 · CT.gov ↗
What to watch
Phase 2Recurrent GlioblastomaRecruiting
Est. primary completion 2027-12-30 · NCT06220552 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT06962189 · CT.gov ↗
What to watch
Phase 2Locally Advanced Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT06752382 · CT.gov ↗
What to watch
Phase 2HCC - Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07521852 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell Carcinoma (ESCC)Recruiting
Est. primary completion 2027-12-31 · NCT06709417 · CT.gov ↗
What to watch
Phase 2Recurrent or Metastatic Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07581821 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-12-31 · NCT07398326 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Esophagogastric Junction AdenocarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT06761846 · CT.gov ↗
What to watch
Phase 2/3Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2027-12-31 · NCT07490262 · CT.gov ↗
What to watch
Phase 3Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate, MPR …Recruiting
Est. primary completion 2027-12-31 · NCT06925243 · CT.gov ↗
What to watch
Phase 4Thyroid NeoplasmsNot yet recruiting
Est. primary completion 2027-12-31 · NCT07010393 · CT.gov ↗
What to watch
Early phase / not applicableLocally Advanced Rectal Cancer (LARC)Not yet recruiting
Est. primary completion 2027-12-31 · NCT07738042 · CT.gov ↗
What to watch
2028 (33)
January 2028 (2)
March 2028 (4)
Phase 2NKTCLNot yet recruiting
Est. primary completion 2028-03-06 · NCT07574528 · CT.gov ↗
What to watch
Phase 2Hepato Cellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2028-03-17 · NCT07487662 · CT.gov ↗
What to watch
Phase 2Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)Recruiting
Est. primary completion 2028-03-27 · NCT07518602 · CT.gov ↗
What to watch
Early phase / not applicableRectal Cancer, AdenocarcinomaRecruiting
Est. primary completion 2028-03-31 · NCT07474103 · CT.gov ↗
What to watch
April 2028 (3)
Phase 2Gastric Cancer (GC), AFP Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2028-04-01 · NCT07515625 · CT.gov ↗
What to watch
Phase 3MSI-HActive not recruiting
Est. primary completion 2028-04-15 · NCT05890742 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-04-30 · NCT06313190 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Colorectal CancerRecruiting
Est. primary completion 2028-05-31 · NCT06497985 · CT.gov ↗
What to watch
June 2028 (9)
Phase 2HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2028-06 · NCT07490990 · CT.gov ↗
What to watch
Phase 2Locally Advanced Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-06 · NCT07781072 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-06-01 · NCT07603661 · CT.gov ↗
What to watch
Phase 2Colorectal NeoplasmsNot yet recruiting
Est. primary completion 2028-06-01 · NCT07535632 · CT.gov ↗
What to watch
Phase 3Esophageal CancerActive not recruiting
Est. primary completion 2028-06-01 · NCT07306663 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-10 · NCT07410975 · CT.gov ↗
What to watch
Phase 2Biliary Tract Cancer (BTC)Not yet recruiting
Est. primary completion 2028-06-15 · NCT07638501 · CT.gov ↗
What to watch
Phase 1Colorectal Cancer, Gastric Cancer, Ovarian CancerRecruiting
Est. primary completion 2028-06-30 · NCT05427487 · CT.gov ↗
What to watch
Phase 2Biliary Tract Cancers (BTC)Active not recruiting
Est. primary completion 2028-06-30 · NCT07654530 · CT.gov ↗
What to watch
July 2028 (2)
August 2028 (1)
Phase 2Pirtobrutinib, Sintilimab, Central Nervous System LymphomaRecruiting
Est. primary completion 2028-08-05 · NCT07416890 · CT.gov ↗
What to watch
September 2028 (3)
Phase 2TNBC - Triple-Negative Breast CancerRecruiting
Est. primary completion 2028-09-25 · NCT07351487 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2028-09-30 · NCT07194005 · CT.gov ↗
What to watch
Phase 2ORR,OS,PFSNot yet recruiting
Est. primary completion 2028-09-30 · NCT07328802 · CT.gov ↗
What to watch
October 2028 (2)
December 2028 (6)
Phase 1Advanced HBV-Related Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-12 · NCT07557251 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2028-12-01 · NCT07331883 · CT.gov ↗
What to watch
Phase 2PCNSL, Primary Central Nervous System LymphomaRecruiting
Est. primary completion 2028-12-31 · NCT07350850 · CT.gov ↗
What to watch
Phase 2Ovarian Cancer, Ovarian Clear Cell CarcinomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07239622 · CT.gov ↗
What to watch
Phase 2Rectal Cancer, RadiotherapyRecruiting
Est. primary completion 2028-12-31 · NCT07646639 · CT.gov ↗
What to watch
Phase 2Locally Advanced Gastric CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07638631 · CT.gov ↗
What to watch
2029 (23)
January 2029 (2)
February 2029 (1)
Phase 2Gastric Cancer or Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2029-02-20 · NCT07492615 · CT.gov ↗
What to watch
March 2029 (2)
April 2029 (2)
May 2029 (1)
Phase 2Hepatocellular Carcinoma (HCC), Bone MetastasesNot yet recruiting
Est. primary completion 2029-05-30 · NCT07537972 · CT.gov ↗
What to watch
June 2029 (4)
Phase 1Advanced / Metastatic Solid TumorRecruiting
Est. primary completion 2029-06 · NCT07455617 · CT.gov ↗
What to watch
Phase 2Rectal CancerRecruiting
Est. primary completion 2029-06-01 · NCT07594925 · CT.gov ↗
What to watch
Early phase / not applicableComplete Remission Rate， CRR, Progression Free Survival, Overall Survival, Adverse Event, Duration of ResponseNot yet recruiting
Est. primary completion 2029-06-01 · NCT07542912 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-06-26 · NCT07120698 · CT.gov ↗
What to watch
July 2029 (3)
Early phase / not applicableEndometrial Cancer, Endometrioid Carcinoma, Mismatch Repair DeficiencyRecruiting
Est. primary completion 2029-07 · NCT06549855 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerNot yet recruiting
Est. primary completion 2029-07-15 · NCT07683221 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal Adenocarcinoma, Liver Neoplasms, Lung NeoplasmsNot yet recruiting
Est. primary completion 2029-07-31 · NCT07745790 · CT.gov ↗
What to watch
September 2029 (3)
Early phase / not applicableChronic Hepatitis BNot yet recruiting
Est. primary completion 2029-09 · NCT07809165 · CT.gov ↗
What to watch
Phase 1/2HCC - Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2029-09-30 · NCT07761286 · CT.gov ↗
What to watch
Phase 2Mucosal Melanoma, PD-L1 PositiveRecruiting
Est. primary completion 2029-09-30 · NCT07400302 · CT.gov ↗
What to watch
October 2029 (1)
Early phase / not applicablePrimary Central Nervous System Lymphoma (PCNSL)Not yet recruiting
Est. primary completion 2029-10-01 · NCT07198464 · CT.gov ↗
What to watch
December 2029 (4)
Phase 1/2HIV, AIDS, Immune Checkpoint Inhibitors, Refractory Opportunistic InfectionNot yet recruiting
Est. primary completion 2029-12 · NCT07579247 · CT.gov ↗
What to watch
Phase 2Renal Cell Carcinoma (Kidney Cancer), Immunotherapy, Molecular Targeted TherapyNot yet recruiting
Est. primary completion 2029-12 · NCT07715565 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2029-12-30 · NCT07756190 · CT.gov ↗
What to watch
Phase 2Lung Cancer Stage IIIRecruiting
Est. primary completion 2029-12-31 · NCT03872661 · CT.gov ↗
What to watch
2030 (8)
January 2030 (1)
Phase 3Local Advanced Rectal Cancer, PD-1 Inhibitor, PCSK9 Inhibitor, RCT, Radiotherapy, Capecitabine, OxaliplatinNot yet recruiting
Est. primary completion 2030-01-01 · NCT07686796 · CT.gov ↗
What to watch
April 2030 (1)
Phase 3Nasopharyngeal Carcinoma (NPC)Recruiting
Est. primary completion 2030-04-01 · NCT07459296 · CT.gov ↗
What to watch
May 2030 (2)
June 2030 (1)
Phase 2CLDN18.2 Positive, Primary Gastric Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2030-06-30 · NCT07483567 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2MMRd Endometrial Cancer of Stage I~IINot yet recruiting
Est. primary completion 2030-07-20 · NCT07731607 · CT.gov ↗
What to watch
December 2030 (2)
2031 (3)
January 2031 (1)
Phase 3Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal CancerRecruiting
Est. primary completion 2031-01-01 · NCT05357846 · CT.gov ↗
What to watch
May 2031 (1)
Phase 3Hepatocellular Carcinoma (HCC), MetastasesNot yet recruiting
Est. primary completion 2031-05-30 · NCT07537946 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2/3Resectable Gastric/Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2031-12-31 · NCT07643623 · CT.gov ↗
What to watch
2033 (1)
June 2033 (1)
Phase 2Natural Killer/T-cell LymphomaNot yet recruiting
Est. primary completion 2033-06-30 · NCT07768943 · CT.gov ↗
What to watch
2036 (1)
June 2036 (1)
Phase 2Unresectable/Metastatic Gastric CancerNot yet recruiting
Est. primary completion 2036-06 · NCT06365008 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.